ivabradine has been researched along with Chagas Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bocchi, EA; Guimarães, GV; Rassi, S | 1 |
| Demacq, C; Gimpelewicz, CR; Gómez, EA; Martinez, F; McMurray, JJV; Packer, M; Ramires, FJA; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR | 1 |
1 trial(s) available for ivabradine and Chagas Disease
| Article | Year |
|---|---|
Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial.
Topics: Argentina; Brazil; Cardiovascular Agents; Chagas Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Survival Rate; Treatment Outcome; Ventricular Function, Left | 2018 |
1 other study(ies) available for ivabradine and Chagas Disease
| Article | Year |
|---|---|
Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et
Topics: Chagas Cardiomyopathy; Chagas Disease; Heart; Heart Failure; Humans; Ivabradine | 2018 |